Log in

Login to your account

Username *
Password *
Remember Me
LPMA logo
LPMA logo
Member Quick Links


 

Find a Psychiatrist
Find a Psychiatrist
Visit the American Psychiatric Association Quick Search.
Search Now »
Public Resources
Public Resources
We have provide a few helpful links and information.
More Info »
Calendar
Calendar of Events
Mark your calendar for upcoming events and CME opportunities.
Upcoming Events »
Newsletters
Newsletters
Browse our newsletter articles and archives dating back to 1961.
Read Now »
Coronavirus (COVID-19)
Coronavirus (COVID-19)
Resources and Louisiana Testing Sites & Vacation Locations.
Information Hub »


 

Psychiatric News Alert

  • Lybalvi Approved for Schizophrenia, Bipolar I Disorder in Adults

    Psych News Alert Jun 11, 2021 | 17:49 pm

    Lybalvi Approved for Schizophrenia, Bipolar I Disorder in Adults The Food and Drug Administration (FDA) has approved Lybalvi (olanzapine and samidorphan) for the treatment of schizophrenia in adults, Alkermes announced. The agency also approved Lybalvi for the treatment of bipolar I disorder in adults, as a monotherapy for maintenance, and as a monotherapy or an adjunct to lithium or valproate for the acute treatment of manic or mixed episodes. Olanzapine is an antipsychotic, and samidorphan is a new chemical[…]

    Read more...